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Abstract (99 words)
Reducing treatment burden in cystic fibrosis (CF) is the top research priority for patients and 
clinicians. Difficulty accessing medication is one aspect of treatment burden. We investigated 
this with an online survey available globally for CF patients and health care professionals. 
Almost three quarters of CF patients in our survey report difficulty getting repeat 
prescriptions on time and most community pharmacists experience interrupted supplies of CF 
specific medications. These barriers affect emotional and physical health of people with CF. 
Two thirds of people with CF would like to get all their CF medication from one place, their 
CF centre.
Introduction
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Reducing treatment burden for patients with CF was voted the number one research priority 
by people with CF (pwCF), their parents/carers and healthcare professionals in a James Lind 
Alliance Priority Setting Partnership. (1) ‘Treatment burden’ describes the increased 
workload associated with health care affecting individuals’ physical and psychological 
wellbeing (2).  The James Lind CF2 project further explored this research priority. 
CF is a multisystem disease requiring complex treatment including specialist medications 
(e.g. inhaled antibiotics and CFTR modulators) and non-specialist drugs (e.g. bronchodilators 
and multivitamins), the latter being drugs which are used almost exclusively in the treatment 
of pwCF which are usually prescribed by the CF team. High treatment burden is common to 
many chronic diseases, resulting in reduced adherence, wasted medication, health 
deterioration and poorer quality of life. (3)(4) Treatment burden for pwCF is considerable – 
most spend around two hours per day on treatment. (5) Accessing prescribed medications is 
an issue for patients with chronic diseases which contributes to treatment burden. (6) We 
aimed to review the obstacles pwCF encounter when accessing medications and to 
demonstrate insight from professionals who provide medications (pharmacists and primary 
care doctors). 
Methods
The James Lind CF2 project explores in depth some of the research priorities identified by 
the James Lind Alliance priority setting partnership for CF. (1) It is supported by the UK 
National Institute for Health Research (NIHR) and the UK CF Trust. An online survey for 
pwCF was conducted generating free-text data on accessing medications (5). A further survey 
for primary care doctors and community pharmacists (with guidance from a focus group) was 
distributed using SurveyMonkeyTM and was available for 4 weeks in June 2019. Both 
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quantitative ‘single answer’ and qualitative ‘free text’ questions were incorporated. A final 
questionnaire to pwCF (July 2019) asked; ‘should all medication be accessed from secondary 
care?’. 
The questionnaires were not country-restricted and were promoted via social media. They 
were anonymous; no personal data were stored, or financial incentive given. All responses to 
the questionnaires were non-compulsory.  Data were downloaded into Excel for quantitative 




James Lind CF2 question “Do you ever have difficulties getting the medications you need 
from your GP/Pharmacist/hospital/homecare?” found 76% (241/317) of pwCF had difficulty 
accessing medication (5). The demographics of the participants have previously been 
published (5). Of the pwCF who had difficulty accessing medication, 65 participants 
expanded with a free text response following on from the quantitative question. Six recurring 
themes were identified. (Figure 1) Emotive language was used in free-text responses 
describing challenges that pwCF experienced in accessing their medication (Figure 2). 
The healthcare professionals’ survey yielded 256 responses, including 249 from the UK. 
Almost a third of respondents did not have pwCF in their cohort (31%; 78/249), with the 
majority having one or two pwCF 45% (114/249). Primary care doctors accounted for 16% of 
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the responses (40/249). Data on prescribing revealed that 39% (13/33) lacked confidence 
when prescribing CF specialist medication and 50% (17/34) had been asked to prescribe 
medication that should be prescribed by secondary care.  Suggestions on how the CF centre 
can support primary care included education, ensuring up-to-date guidelines and having 
access to discuss care. Many pwCF did not see value from primary care doctors’ input, and 
some primary care doctors felt that their role was ‘limited as there is such good access to 
specialists’. However, others perceived their role to be caring for the pwCF outside of the CF 
condition, ‘including mental health, contraception, and vaccinations’.
Community pharmacists describe their role as a medication dispenser to ensure continuous 
treatment and optimising adherence. Difficulties obtaining medication supplies are reported 
by 55% (52/94) of community pharmacists including: pancreatic enzyme replacement 
therapy; dornase alfa; CF specific vitamin preparations; and colistimethate sodium. ‘Supply 
problems are a major issue, this is not a pharmacy problem but industrial pharmaceutical 
companies causing the delay’. Some specialist medications have a quota restricting supply, 
‘for example a manufacturer restricts supply to 2 per month, but you have a script for 12’. 
Expensive medications with short shelf-lives are not kept in stock because of the potential for 
waste if treatment is changed. For routine repeat-prescriptions, 48% (95/196) of pharmacies 
require 1-2 days’ notice. For specialist medication 39% (75/196) of pharmacies require 3-4  
days’ notice with 10% (19/196) requiring 1-2 weeks’ notice. Only 40% (76/192) of these 
have online repeat prescriptions requests.  
PwCF and health care professionals were asked if all medication should be prescribed and 
accessed in secondary care (Figure 3). Overall, 65% (25/40) pwCF wanted to access 
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medication from secondary care. Reservations included travel distance, car parking and 
hospital pharmacy delays.  
Discussion 
We present a complex process undertaken by pwCF to access medication, including 76% of 
those surveyed expressing difficulty getting repeat prescriptions from primary care. Our data 
suggest that this is part of the high treatment burden impacting upon physical and mental 
health. 
Although each group interviewed has specific difficulties and frustrations, all are agreed on 
the need to simplify the process. Research shows that patients with chronic diseases have 
difficulty accessing medication, issues including pharmacy stock, medication errors and short 
durations of prescriptions (7) – all issues raised in our study. This is exacerbated by the 
number of medications pwCF take (average 8 daily) (8). 
Primary care doctors and community pharmacists describe the barriers to accessing 
medication including practitioners’ lack of familiarity with specialist medication and 
interrupted supplies. A guide to improving the logistics of obtaining medicines in the 
community offers pwCF and their families, practical suggestions on how to reduce such 
difficulties (9). Primary care doctors suggested that better communication with the CF centre 
and accessible guidelines would support their prescribing. The UK National Health Service 
(NHS) long-term plan (2019) aims for electronic prescribing (10) which may improve 
communication between the CF centre and primary care. 
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Our study has limitations. Respondents were self-selected and those with negative 
experiences might be more motivated to participate. We did not survey CF centres. Not every 
respondent answered every question. The CF patient cohort responding to ‘Should all 
medication be accessed from secondary care?’ was a smaller group than the James Lind CF2 
initial survey. We did not enquire as to whether a delivery service would aid access to 
medications. The surveys were conducted prior to the COVID-19 pandemic which might 
have altered responses, if patients were apprehensive about the infection risk in attending 
hospital. The strengths include the global reach and large number of responses to our original 
survey (941 responses from 21 countries) (1). 
Conclusion
Accessing medication is a problem for pwCF adding to the high treatment burden, impacting 
upon both the emotional and physical health. The next step is for targeted quality 
improvement plans to help reduce treatment burden.
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Figure 1. Quotations from pwCF and their families for each theme identified. GP= General Practitioner 
(Primary care doctor) 
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Figure 2. 1. Inner flow chart depicts the journey to accessing medications where the patient does not have a 
chronic, multisystem disease. The outer circle is a pathway described by the CF patient group that they take 
to access medications 2. Emotive language used by the patient group to describe the cycle in 1. 
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Figure 3. Should all medications be accessed from secondary care? Responses from the CF population, 
Community pharmacists and primary care. 1. For those that answered ‘No’ if travel was not an issue, would 
they change their mind? 2. For primary care doctors who said ‘No’, how many were confident at prescribing   
73x59mm (400 x 400 DPI) 
Page 13 of 12
https://mc.manuscriptcentral.com/thorax
Thorax
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
